Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
选择性 JAK1/2 抑制剂 INCB018424 的临床前表征:对治疗骨髓增生性肿瘤的治疗意义
期刊:Blood
影响因子:21
doi:10.1182/blood-2009-04-214957
Alfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, Taghi Manshouri, Jun Li, Peggy A Scherle, Eian Caulder, Xiaoming Wen, Yanlong Li, Paul Waeltz, Mark Rupar, Timothy Burn, Yvonne Lo, Jennifer Kelley, Maryanne Covington, Stacey Shepard, James D Rodgers, Patrick Haley, Hagop Kantarjian, Jordan S Fridma